The Latest "Buzz on the Street" Show: Featuring NutraLife Biosciences (OTCQB: NLBS) Coverage | Financial Buzz

The Latest “Buzz on the Street” Show: Featuring NutraLife Biosciences (OTCQB: NLBS) Coverage’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “NutraLife Biosciences (NLBS) Announces New Phytocannabinoid Rich (PCR Pure) Water Enhancing Product Line.”

NutraLife Biosciences, Inc. (OTCQB: NLBS) to launch a new line of Phytocannabinoid rich (PCR) water enhancing drops under its new in-house brand PCR Pure.  NutraLife’s new CBD water enhancers will initially be available in four flavors: strawberry, grape, coconut and watermelon. Each 2 oz. bottle will contain 15 servings and have 20 mg per serving or 300 mg per bottle of PCR hemp extract.  The new water enhancers are infused with the extract and can be added to water or other beverages to help support overall health and wellness. 

NutraLife Biosciences, Inc. operates a multifaceted life sciences company. For more than 6 years the Company has manufactured and distributed private label and branded nutraceutical and wellness products. The Company launched its hemp-based CBD products in 2017. Through its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., NutraLife provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction and processing. 

Hemp, a derivative of the cannabis plant, has been used for centuries due to its multi-faceted nature. Hemp, for instance, is used to manufacture textiles, paper, construction materials, and fuel. Most commonly, hemp is known for being derived from the cannabis plant, which has caused it to be classified as a drug under international regulations. However, while unlike marijuana, hemp does not cause psychoactive effects, marijuana and hemp actually offer similar therapeutic benefits. The two differ heavily in the biological makeup of their THC and CBD compounds however; Marijuana contains significantly more THC, which causes the psychoactive effects. On the other hand, hemp contains minimal traces of THC, but contains more CBD. Medical institutions are now reevaluating hemp and its derivatives in order to leverage it for medical uses as CBD can be used to treat medical conditions such as chronic pain, neurological disorders and epilepsy. Furthermore, the U.S. Food and Drug Administration approved its first CBD-derived drug in 2018, Epidiolex, which is used to treat seizures in patients associated with Lennox-Gastaut syndrome or Dravet syndrome. The FDA’s move to approve Epidiolex adds credibility to the cannabis industry, demonstrating that it can potentially become an alternative to traditional medications. According to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million in 2017. The research suggests that the industry is expected to grow to USD 1.9 Billionby 2022, and at a CAGR of 14.4% during the 5-year period. 

In 2017, hemp-derived CBD products accounted for the largest market share as the segment delivered sales of USD 190 Million, accounting for 23% of the overall market in 2017. Sales from the food, personal care, and industrial applications also contributed to a significant portion of the market share. By 2022, Hemp Business Journal forecasts that hemp-derived CBD products will continue to dominate the market, driving in USD 646 Million in sales. The rapid expansion of the CBD marketplace has led to the emergence of new CBD-based products. Consumers can now more easily find CBD products in their local pharmaceutical stores or even a convenience store. The CBD market can accelerate even further if clinical trials progress and report positive data, since the FDA requires effective, large-scale trials in order to evaluate cannabis as a form of treatment. Researchers from the University of Minnesota’s (U of M) College of Biological Sciences and College of Food, Agricultural, and Natural Resource Sciences are one of the handfuls of groups that are federally authorized to study cannabis. The researchers have argued they have “indisputable evidence” that hemp and marijuana should be separated, according to Mercola. “It’s a plant of major economic importance that is very poorly understood scientifically. With this study, we have indisputable evidence for a genetic basis of differences among cannabis varieties, further challenging the position that all cannabis should be regulated as a drug,” said George Weiblen, a professor with a joint appointment in the U of M’s College of Biological Sciences and College of Food, Agricultural and Natural Resource Sciences.

For more information, please visit: NutraLife Biosciences, Inc.

For more corporate news on NutraLife Biosciences, Inc., check out the Buzz on the Street

About Buzz on the Street: One of’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For nutralife biosciences inc. financial and corporate news dissemination, has been compensated four thousand dollars by meridian ventures. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: